Human monoclonal antibodies to interleukin-5
View Patent ↗The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.
1. An antibody or antigen-binding fragment thereof that specifically binds IL-5, wherein said antibody or antigen-binding fragment comprises:
(a) a heavy chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 8, 10, and 12, respectively; and
(b) a light chain amino acid sequence comprising the CDR1, CDR2 and CDR3 amino acid sequences shown in SEQ ID NOS: 14, 16, and 18, respectively.
2. A composition comprising the antibody or antigen-binding fragment thereof according to claim 1 , and a pharmaceutically acceptable carrier.
3. A kit comprising the antibody or antigen-binding fragment thereof according to claim 1 .
4. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is a Fab fragment.
5. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is a Fab′ fragment.
6. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is a F(ab′) 2 fragment.
7. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is an Fv fragment.
8. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is an Fd fragment.
9. The antibody or antigen-binding fragment thereof according to claim 1 , wherein said fragment is an dAb fragment.